Researchers discuss how psychedelics can affect the brain and provide therapeutic benefits for those suffering from a range of psychiatric disorders.
Genetic variants of the 5-HT2A serotonin receptor may explain why some respond to psychedelic therapies for the treatment of mental health disorders while others don't.
Researchers critique the latest findings on serotonin's role in depression and report people should maintain their current therapies to help control their symptoms of depression.
Researchers explain why the serotonin hypothesis for depression may not be as accurate as previously believed.
A new comprehensive review disputes the serotonin theory of depression, reporting there remains no clear evidence that serotonin levels or serotonin activity is responsible for depression.
Triptans, drugs commonly prescribed for migraine relief, may be effective for the treatment of obesity. Daily triptan exposure led to reduced food intake and increased weight loss in mouse models.
Medications that block serotonin and dopamine enable the life extension effect of the FMO protein in C. elegans, even in the presence of the smell of food.
Researchers have resolved the structures of all 12 serotonin receptor subtypes.
A new rat study exposed to everyday endocrine-altering chemicals, such as BPA during pregnancy, interfered with fetal brain development.
A new study will explore how psilocybin affects different networks and serotonin function in the brains of autistic adults.
Researchers explore the effect psychedelics have on the brain and how they are effective at treating depression.
Hyperactivity in a serotonin-dopamine circuit in the brain appears to be responsible for persistent anorexia in animal models. The DRD1 receptor appears to drive the hyperactivity. Deleting the DRD1 gene restored normal eating behaviors in animals.
